A. Menarini Diagnostics and Nucleix have announced a strategic commercial agreement to exclusively market the Bladder EpiCheck® test in Europe. This non-invasive, CE-marked urine test is designed to detect and monitor bladder cancer and upper tract urothelial carcinoma (UTUC), providing an alternative to invasive cystoscopy.
The partnership was revealed at the 36th European Congress of Pathology in Florence, where both companies highlighted the potential impact of the Bladder EpiCheck test. It is included in the European Association of Urology (EAU) Clinical Guidelines, supporting its use in both diagnosis and surveillance of non-muscle invasive bladder cancer (NMIBC) and UTUC. The test could reduce the frequency of cystoscopies for bladder cancer patients, improving their outcomes and easing the burden on healthcare systems.
Chris Hibberd, CEO of Nucleix, expressed optimism about working with Menarini Diagnostics, citing their extensive reach across Europe as a key factor in expanding the test’s availability. Fabio Piazzalunga, General Manager of Menarini Diagnostics, emphasized the significance of the partnership in bringing innovative diagnostic solutions to market and providing a non-invasive option for bladder cancer detection.
Nucleix, a leader in liquid biopsy technology, leverages its expertise in early cancer detection using methylation-based testing. The company is also advancing its Lung EpiCheck® test for commercialization.
This alliance between A. Menarini Diagnostics and Nucleix aims to enhance bladder cancer care across Europe through the adoption of the Bladder EpiCheck® test.
For more information visit: https://www.prnewswire.com/news-releases/a-menarini-diagnostics-and-nucleix-announce-a-strategic-partnership-for-a-non-invasive-bladder-cancer-test-in-europe-302241244.html
